Revisiting the Warburg effect: historical dogma versus current understanding.
Level 5 - mechanism / opinion, no new human data
Narrative mechanistic review with no primary empirical data or systematic search methodology
PubMed 33347611 · doi:10.1113/JP278810
What was done
This review synthesized current mechanistic evidence on the Warburg effect, contrasting Otto Warburg's historical premise of irreversible mitochondrial damage with modern molecular genetics and oncogenic signaling pathways.
What was found
The abstract reports no quantitative values or statistical comparisons. It describes that in most tumors, accelerated aerobic glycolysis arises from the interplay of hypoxia-inducible factor-1 (HIF-1), oncogenes (cMyc, Ras), loss of tumor suppressors (mutant p53, PTEN), and signaling pathways (PI3K-Akt-mTORC1, MAPK, Jak-Stat3), rather than permanent mitochondrial impairment. This metabolic switch supports biosynthesis, rapid ATP generation per unit time, extracellular acidification via lactate and proton transporters (MCT4, carbonic anhydrases), redox homeostasis, and immune suppression. Primary mitochondrial defects drive the Warburg effect in only a minority of tumors.
Why it matters
It clarifies that tumor mitochondria are generally functional, shifting the paradigm from energetic compensation due to damage to active oncogenic reprogramming that promotes survival, proliferation, and therapy resistance.
Limits
The abstract describes a narrative conceptual review with no primary data, sample size, or systematic search protocol. Findings represent biological mechanism and theory rather than direct clinical outcomes.
Cited by
- context Hypoxia in an expanding tumor mass damages mitochondria, causing aggressive cancer cells to shift away from oxidative phosphorylation toward glycolysis relying on fermentable fuels like glucose and glutamine.